

*Biopharmaceutical Contract Manufacturing 2011:
New Participants, Expanded Services and
Emerging Markets*

Table of Contents

Presented by

HighTech Business Decisions

3150 Almaden Expressway, Suite 222, San Jose, CA 95118

Tel: (408) 978-1035 Fax: (408) 978-8925

www.hightechdecisions.com

October 2011

Biopharmaceutical Contract Manufacturing 2011: New Participants, Expanded Services and Emerging Markets

TABLE OF CONTENTS

Chapter 1:	EXECUTIVE SUMMARY	
	1.1 Introduction	1-1
	1.2 Market Overview	1-2
	1.2.1 Introduction	1-2
	1.2.2 Industry Drivers	1-2
	1.2.3 Market Size	1-4
	1.3 Summary of Customer Needs	1-5
	1.3.1 Products	1-5
	1.3.2 Outsourcing Strategies	1-7
	1.3.3 Outsourcing Budgets	1-8
	1.3.4 Current Market Conditions Impact on CMO Pricing	1-10
	1.3.5 Industry Trends and Observations	1-11
	1.4 Summary of Contractors' Capabilities	1-13
	1.4.1 Annual Revenue Ranges	1-13
	1.4.2 Technology Capabilities	1-14
	1.4.3 Capacity	1-15
	1.4.4 Expectations for the Future of the Industry	1-16
<hr/>		
Chapter 2:	METHODOLOGY, DEFINITIONS, AND ACRONYMS	
	2.1 Research Objectives	2-1
	2.2 Research Methodology	2-1
	2.3 Definition of Biopharmaceutical Manufacturing	2-3
	2.4 Box-and-Whiskers Plot Definition	2-4
	2.5 Acronyms	2-4
<hr/>		
Chapter 3:	BIOPHARMACEUTICAL CONTRACT MANUFACTURING: MARKET OVERVIEW	
	3.1 Introduction	3-1
	3.2 Suppliers: The Contract Biomanufacturers	3-2
	3.2.1 Types of Contract Biomanufacturing Companies	3-2
	3.2.2 Major Players: Contract Biomanufacturing Companies	3-4
	3.2.3 Organizational Changes in the Industry	3-6
	3.2.4 Technologies and Services	3-8
	3.2.5 Contract Biomanufacturers' Capacities	3-8
	3.2.6 Contractor Revenues	3-11

Biopharmaceutical Contract Manufacturing 2011: New Participants, Expanded Services and Emerging Markets

TABLE OF CONTENTS (continued)

Chapter 3:	3.3 The Customers: Pharmaceutical and Biotechnology Companies	3-12
	<i>3.3.1 Outsourced Biomanufacturing</i>	3-12
	<i>3.3.2 Outsourcing Biomanufacturing by Production Technology</i>	3-14
	<i>3.3.3 Examples of Contractors Used by Client Companies</i>	3-16
	<i>3.3.4 Customers' Future Outsourcing Expectations</i>	3-20
	<i>3.3.5 Capacity</i>	3-21
	3.4 Industry Drivers	3-26
	<i>3.4.1 Capacity</i>	3-26
	3.5 Market Size	3-30
	<i>3.5.1 Estimates of Market Size Based on Contractor Revenue</i>	3-30
	<i>3.5.2 Market Size by Technology and Service Categories</i>	3-31
	3.6 Market Growth Forecasts	3-32
	3.7 Trends in the Biopharmaceutical Contract Mfg. Market	3-34
	<i>3.7.1 Industry Opportunities and Challenges</i>	3-34
	<i>3.7.2 Overall Industry Trends</i>	3-36
<hr/>		
Chapter 4:	PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES: CLIENT ANALYSIS	
	4.1 Introduction	4-1
	4.2 Respondent Company Backgrounds	4-2
	<i>4.2.1 Respondents' Titles and Experience</i>	4-2
	<i>4.2.2 Locations and Sites</i>	4-3
	<i>4.2.3 Respondents' Biopharmaceutical Products on Market</i>	4-5
	<i>4.2.4 Respondents' Clinical and Commercial Products</i>	4-6
	<i>4.2.5 Respondents' Outsourced Products</i>	4-10
	4.3 Biomanufacturing Needs	4-15
	<i>4.3.1 Current and Forecast Biomanufacturing Needs</i>	4-15
	<i>4.3.2 Current Internal Capacity and Plans to Build</i>	4-20
	<i>4.3.3 Preclinical Products</i>	4-23
	<i>4.3.4 Future Production Technology Requirements</i>	4-27
	4.4 Biomanufacturing Strategies	4-29
	<i>4.4.1 Overall Biomanufacturing Strategies</i>	4-29
	<i>4.4.2 Outsource versus In-House Capacity</i>	4-35
	<i>4.4.3 Estimating Future Outsourcing Requirements</i>	4-39
	<i>4.4.4 Potential for Second Source Contracting</i>	4-46
	<i>4.4.5 Outsourcing of New Projects</i>	4-50

Biopharmaceutical Contract Manufacturing 2011: New Participants, Expanded Services and Emerging Markets

TABLE OF CONTENTS (continued)

Chapter 4:	4.5 Outsourcing Biomanufacturing	4-51
	4.5.1 <i>Percentage Outsourced and Expected to Be Outsourced</i>	4-51
	4.5.2 <i>Current and Anticipated Needs for Outsourced Services</i>	4-55
	4.5.3 <i>Importance of Outsource Services</i>	4-57
	4.5.4 <i>New Services Sought in a Contractor</i>	4-60
	4.6 Biomanufacturing Technologies	4-65
	4.6.1 <i>Current Expression Levels</i>	4-65
	4.6.2 <i>Release Procedure for APIs Produced at the Contractor</i>	4-67
	4.6.3 <i>Disruptive Technologies</i>	4-71
	4.7 Contractor Selection	4-77
	4.7.1 <i>How Potential Contract Partners are Found</i>	4-78
	4.7.2 <i>Users' CMO Search Timelines</i>	4-79
	4.7.3 <i>Essential Characteristics Sought in a Contractor</i>	4-87
	4.7.4 <i>Must Have Requirement for Evaluation of CMO Proposal</i>	4-94
	4.7.5 <i>First Filter for Determining Short List of CMO Proposals</i>	4-97
	4.7.6 <i>New CMO Searches via Internet</i>	4-101
	4.7.7 <i>Attributes for Selecting a CMO in China or India</i>	4-106
	4.7.8 <i>Challenges of Outsourcing to CMO in Low-Cost Region</i>	4-110
	4.7.9 <i>Possible Asian CMO Competitors</i>	4-117
	4.7.10 <i>Biologic API Production Moving to Asian CMOs</i>	4-122
	4.8 Contractor Relationships	4-124
	4.8.1 <i>Current Contractors Used by Service</i>	4-124
	4.8.2 <i>Favorite Contractors</i>	4-128
	4.8.3 <i>Preferred Time Range for Duration of CMO Contract</i>	4-134
	4.8.4 <i>Preferred Outsourcing Service Model</i>	4-138
	4.8.5 <i>Other Service Models</i>	4-142
	4.9 Outsource Spending	4-148
	4.9.1 <i>Outsourcing Budgets</i>	4-148
	4.9.2 <i>Outsourcing Budgets by Technology</i>	4-151
	4.9.3 <i>Outsourcing Budgets by Service</i>	4-153
	4.9.4 <i>Market Impact of CMO Pricing</i>	4-156
	4.9.5 <i>Reservation Fees: Users' Expectations</i>	4-159
	4.9.6 <i>CMO Material and Supply Markup Charges</i>	4-163
	4.10 Future Trends and Expectations	4-168
	4.10.1 <i>Trends in Outsourcing API Development versus GMP Manufacture</i>	4-168
	4.10.2 <i>Future Large-Scale Production Facilities</i>	4-172
	4.10.3 <i>Issues and Trends in Biosimilars</i>	4-179
	4.10.4 <i>The Future of the Biopharmaceutical Contract Manufacturing Industry</i>	4-185

Biopharmaceutical Contract Manufacturing 2011: New Participants, Expanded Services and Emerging Markets

TABLE OF CONTENTS (continued)

Chapter 5: BIOPHARMACEUTICAL CONTRACT MANUFACTURERS

5.1 Introduction	5-1
5.1.1 <i>Study Participants</i>	5-1
5.1.2 <i>Types of Suppliers</i>	5-2
5.1.3 <i>Locations and Areas of Expertise</i>	5-4
5.1.4 <i>Acquisitions and Organizational Changes</i>	5-10
5.1.5 <i>Revenues</i>	5-12
5.2 Technologies and Capacities Offered	5-13
5.2.1 <i>Technologies Offered</i>	5-13
5.2.2 <i>Percentage of Business by Service Category</i>	5-16
5.2.3 <i>Contract Manufacturers' Current Capacities</i>	5-21
5.2.4 <i>Contract Manufacturers' Expansion Plans</i>	5-26
5.3 Manufacturing Technologies	5-28
5.3.1 <i>Manufacturing Capability of Commercial Recombinant Products</i>	5-28
5.3.2 <i>Contractor Differentiation</i>	5-31
5.3.3 <i>Instrumentation Most Valuable to Implement PAT</i>	5-35
5.3.4 <i>Proprietary Production Platforms vs. Generic Production Platforms</i>	5-38
5.3.5 <i>Typical Time to Change Products.</i>	5-42
5.3.6 <i>Expected Service Timelines</i>	5-46
5.3.7 <i>Expression Yield and Batch Success Rates</i>	5-47
5.4 Marketing and Customer Relationships	5-49
5.4.1 <i>Request for Proposals</i>	5-49
5.4.2 <i>Trade Shows</i>	5-54
5.4.3 <i>Clients Served</i>	5-58
5.4.4 <i>Projects Worked On</i>	5-59
5.4.5 <i>Characteristics of the Customer Base</i>	5-60
5.4.6 <i>Proportion of Business by World Regions</i>	5-64
5.4.7 <i>Duration of Customer Contracts</i>	5-65
5.4.8 <i>Client-Contractor Relationship Changes</i>	5-68
5.5 Biosimilars	5-72
5.5.1 <i>Biosimilar Strategy</i>	5-73
5.5.2 <i>Biosimilar Projects</i>	5-75
5.5.3 <i>Impact of Biosimilars</i>	5-77

Biopharmaceutical Contract Manufacturing 2011: New Participants, Expanded Services and Emerging Markets

TABLE OF CONTENTS (continued)

Chapter 5:	5.6 Industry and Future Trends	5-80
	<i>5.6.1 Contractor Change in Demand for Outsource Services</i>	5-80
	<i>5.6.2 Contractor Impact of Downturn in Economy</i>	5-83
	<i>5.6.3 Expectation of Industry Growth</i>	5-89
	<i>5.6.4 Preparations for Expected Growth</i>	5-94
	<i>5.6.5 Expectations for the Biopharmaceutical Contract Manufacturing Industry</i>	5-97

Appendix A: Write-Ups of Interviews with 43 Pharmaceutical and Biotechnology Company
BioManufacturing Directors Worldwide, Unnamed and Edited for Confidentiality

Appendix B: Directory of Biopharmaceutical Contract Manufacturers

Appendix C: Interview Guide for Pharmaceutical and Biotechnology Company
Respondents

Appendix D: Interview Guide for Biopharmaceutical Contract Manufacturers

Biopharmaceutical Contract Manufacturing 2011: New Participants, Expanded Services and Emerging Markets

LIST OF TABLES

Chapter 1

1.3-1	Changes in CMO Pricing	1-11
1.3-2	Users' Opinions on Future of the Industry	1-11
1.4-1	Future Trends Noted by CMO Respondents	1-17

Chapter 2

2.2-1	Market Research Steps	2-2
2.5-1	List of Acronyms	2-4

Chapter 3

3.2-1	Respondents' Top Biopharmaceutical Contractors Manufacturers	3-4
3.2-2	Examples of Changes or Events in the CMO Industry: Past Two Years	3-6
3.2-3	Major Contract Biomanufacturing Technology Categories	3-8
3.2-4	Biopharmaceutical Contract Manufacturing Industry Capacity Estimates	3-9
3.2-5	Examples of New Capacity for Biopharmaceutical Contract Manufacturing	3-11
3.3-1	Examples of Customer Companies and Their Contract Biomanufacturers	3-16
3.3-2	Examples of Pharmaceutical/Biotechnology Companies Building Capacity	3-22
3.3-3	Estimates of Totalled Needs for Outsourced Volumes by Respondents	3-24
3.3-4	Estimates of Needs for Outsourced Volumes for the Worldwide Industry	3-26
3.4-1	Outsourced Manufacturing Capacity vs Needs: Mammalian Cell Culture	3-27
3.4-2	Outsourced Manufacturing Capacity vs Needs: Microbial Fermentation	3-29
3.5-1	Worldwide 2010 Market Size for Contract Biomanufacturing: Revenues	3-30
3.5-2	Market Size by Technology Category	3-31
3.5-3	Market Size by Service Category	3-32
3.6-1	Worldwide 2011 Market Size for Contract Biomanufacturing	3-33
3.7-1	Observations on Industry Trends	3-36

Chapter 4

4.1-1	Respondent Pharmaceutical and Biotechnology Companies	4-2
4.2-1	Respondents' Titles by Segment	4-3
4.2-2	Respondent Locations	4-4
4.2-3	Number of Biomanufacturing Sites at Respondent Companies	4-5
4.2-4	Number of Products Produced Using Microbial Technologies	4-7
4.2-5	Number of Products Produced Using Mammalian Technologies	4-7
4.2-6	Types of Respondents' Products by Production Technology	4-9
4.2-7	Outsourced Products by Phase by Year	4-11
4.2-8	Number of Products Outsourced by Tank Size in 2011: Respondent Companies with No Biomanufacturing Sites	4-12
4.2-9	Number of Products Outsourced by Tank Size in 2011: Respondent Companies with One Biomanufacturing Site	4-13
4.2-10	Number of Products Outsourced by Tank Size in 2011: Respondent Companies with Multiple Biomanufacturing Sites	4-13

Biopharmaceutical Contract Manufacturing 2011: New Participants, Expanded Services and Emerging Markets

LIST OF TABLES (continued)

Chapter 4

4.3-1	Respondents' Current and Expected Capacity Needs for Outsourced Products: Large Tank Sizes, Mammalian Cell Culture	4-16
4.3.2	Respondents' Current and Expected Capacity Needs for Outsourced Products: Smaller Tank Sizes, Mammalian Cell Culture	4-17
4.3-3	Respondents' Current and Expected Capacity Needs for Outsourced Products: Large Tank Sizes, Microbial Fermentation	4-18
4.3-4	Respondents' Current and Expected Capacity Needs for Outsourced Products: Smaller Tank Sizes, Microbial Fermentation	4-19
4.3-5	Current Mammalian (Batch) Capacity and Expansions	4-21
4.3-6	Current Microbial Capacity and Expansions	4-22
4.3-7	Current Mammalian (Perfusion) Capacity and Expansions	4-22
4.3-8	Summary: Current Capacity and Expansions at Respondent Sites	4-22
4.3-9	Reasons for Outsourcing Preclinical Production	4-25
4.3-10	Expected Changes in Technologies Used	4-29
4.4-1	Policy for When Outsource Manufacturing Production	4-31
4.4-2	Reasons for Outsourcing When Have In-House Capacity and Capability	4-37
4.4-3	Trends Observed Based on Estimating Future Outsourcing Requirements	4-41
4.4-4	Rationale for Adding or Not Adding a Second Contract Supplier	4-47
4.4-5	Number of New Projects Outsourced Over Last 3 Years by Company Segment	4-51
4.5-1	Outsource Budget Allocated by Production Technology	4-53
4.5-2	Services Currently Outsourced	4-56
4.5-3	Services Planned Outsourced	4-57
4.5-4	No Plans to Outsource Services	4-57
4.5-5	Summary of Service Categories Based on Number of Products	4-58
4.5-6	Importance of Outsource Services	4-59
4.5-7	New CMO Services Sought	4-61
4.6-1	Expression Levels Reported by Respondents in Grams per Liter	4-66
4.6-2	Expression Levels Reported for Mammalian mAb and rProtein Products	4-67
4.6-3	Release Testing and Procedures	4-68
4.7-1	Search Modes for CMOs	4-78
4.7-2	Pre-Approved CMO Partners	4-79
4.7-3	CMO Addition to Approved Vendor List	4-80
4.7-4	CMO Removal from Approved Vendor List	4-81
4.7-5	Essential Characteristics for Choosing a CMO	4-89
4.7-6	Weighted Characteristics Distributed by Number of Manufacturing Sites	4-91
4.7-7	Requirements for Evaluation of CMO Proposal	4-95
4.7-8	Filter for Determining Short List of CMO Proposals	4-98
4.7-9	Top 5 First Filters by Company Segment	4-98
4.7-10	Contract Search Methods	4-102
4.7-11	Additional Attributes for Selecting a CMO in China or India	4-106
4.7-12	Challenges of Outsourcing to Low-Cost Region	4-112
4.7-13	Possible Asian CMO Competitors	4-119
4.7-14	Biologic API Production Being Produced in Asia	4-123

Biopharmaceutical Contract Manufacturing 2011: New Participants, Expanded Services and Emerging Markets

LIST OF TABLES (continued)

Chapter 4

4.8-1	Contract Manufacturers Used by Respondents	4-125
4.8-2	Contract Manufacturers Preferred by Respondents	4-128
4.8-3	Advantages of Alternative Service Models	4-143
4.8-4	Disadvantages of Alternative Service Models	4-143
4.9-1	Expenditures on Outsourcing of Biopharmaceutical Production: 2011	4-149
4.9-2	Expenditures on Outsourcing of Biopharmaceutical Production: 2013	4-150
4.9-3	Average Percentage of Budgets Spent on Each Technology: 2011 and 2013	4-151
4.9-4	Weighted Average Percentage of Budgets Spent on Each Technology	4-153
4.9-5	Simple Average: Percentages of Budgets by Service Expected in 2011	4-153
4.9-6	Simple Average: Percentages of Budgets by Service Expected in 2013	4-153
4.9-7	Weighted Average: Percentages of Budgets by Service Expected in 2011	4-155
4.9-8	Weighted Average: Percentages of Budgets by Service Expected in 2013	4-155
4.9-9	Changes in CMO Pricing	4-156
4.9-10	Initial Payment Terms	4-160
4.9-11	Reasonable Material Markup	4-164
4.9-12	Material Markups	4-164
4.10-1	Trends in Outsourcing API Development and GMP	4-168
4.10-2	Large-Scale Production Facilities	4-173
4.10-3	Trends in Biosimilars	4-179
4.10-3	Future Trends in Biopharmaceutical Contract Manufacturing	4-186

Chapter 5

5.1-1	Respondents from Companies Offering Contract Biomanufacturing Services	5-1
5.1-2	Types of Biopharmaceutical Contract Manufacturers	5-3
5.1-3	Contract Biomanufacturers: Headquarter Locations	5-5
5.1-4	Summary of Respondents' 51 Sites Worldwide	5-6
5.1-5	Examples of Company Changes in Contract Biomanufacturing: Past Two Years	5-10
5.1-6	Organization Changes Over Last Two Years	5-11
5.1-7	2010 Revenues for Contract Biomanufacturers in US\$M	5-12
5.2-1	Business Mix by Production Technology and Year	5-14
5.2-2	Business Mix in 2011 by Production Technology and Contractor Segment	5-15
5.2-3	Averaged Percentages of Business from Biopharmaceutical Services	5-17
5.2-4	2011 Averaged Percentages of Business from Biopharmaceutical Services By Company Type	5-18
5.2-5	Microbial Fermentation Capacity at 14 Respondents' Facilities in 2011	5-22
5.2-6	Mammalian Cell Culture Capacity at 23 Respondents' Facilities in 2011	5-24
5.2-7	Summary of Specialized Technologies Offered By Contractors	5-25
5.2-8	New Capacity Expected: 2012 to 2018	5-26

Biopharmaceutical Contract Manufacturing 2011: New Participants, Expanded Services and Emerging Markets

LIST OF TABLES (continued)

Chapter 5

5.3-1	Technologies that Differentiate CMOs	5-31
5.3-2	Instruments Currently Used to Implement PAT	5-36
5.3-3	Instruments and Technology Needs for Implementing PAT	5-36
5.3-4	Advantages of Proprietary and Generic Expression Systems	5-39
5.3-5	Time Line Activity in Months	5-46
5.3-6	Contractor Yields and Success Rates	5-48
5.4-1	Qualification Prior to Providing Offer for RFP	5-52
5.4-2	Trade Shows Named by Contractors	5-55
5.4-3	Trade Shows for Best Quality Leads	5-56
5.4-4	Trade Shows for Best Technical Information	5-57
5.4-5	Number of Clients in 2010	5-58
5.4-6	Number of Projects Worked on in 2010	5-60
5.4-7	Customers by Simple Average Percentage of Business by Company Type	5-61
5.4-8	Customers by Simple and Weighted Average Percentage of Business	5-61
5.4-9	10 Large Contractors: Types of Customers Served and Number of Projects	5-62
5.4-10	13 Smaller Contractors: Types of Customers Served and Number of Projects	5-62
5.4-11	Average Percentage of Business by Customer Location and Company Type	5-63
5.4-12	Average Percentage of Business from the World Regions by Company Type	5-64
5.4-13	Average Contract Duration (Years)	5-66
5.4-14	Changes in Contractor-Client Relationships	5-69
5.5-1	Impact of Biosimilars	5-77
5.6-1	Reasons for Demand Increase Over Last 12 Months	5-81
5.6-2	Positive Impacts from Recent Economic Downturn	5-83
5.6-3	Negative Business Impact from Recent Economic Downturn	5-87
5.6-4	Average Expectations of Growth: Next Twelve Months	5-90
5.6-5	Average Expectations of Growth: Next Three Years	5-91
5.6-6	Preparations for Expected Growth in Biopharmaceutical Contract Manufacturing	5-94
5.6-6	Industry Prospects and Trends Noted by Contractor Respondents	5-98

Biopharmaceutical Contract Manufacturing 2011: New Participants, Expanded Services and Emerging Markets

LIST OF FIGURES

Chapter 1

1.2-A	Outsourcing Demand vs Contract Biomanufacturers' Capacity: Mammalian	1-3
1.2-B	Outsourcing Demand vs Contract Biomanufacturers' Capacity: Microbial	1-3
1.2-C	Size of Worldwide Biopharmaceutical Contract Manufacturing Market	1-5
1.3-A	Number of Respondents' Biopharmaceutical Products by Phase	1-6
1.3-B	Respondents' Preclinical Products by Company Type	1-6
1.3-C	Respondents Outsourcing Strategies	1-8
1.3-D	Averaged Percentages of Outsourced Production	1-9
1.3-E	Numbers of Respondents Increasing, Decreasing, or Keeping the Same Outsource Percentage	1-9
1.3-F	Changes in CMO Pricing	1-10
1.4-A	Contract Biomanufacturers' Annual Revenue Ranges in 2010	1-13
1.4-B	Technology Comparisons: Average Weighted Percentage of Business 2011	1-14
1.4-C	Worldwide Biopharmaceutical Contract Manufacturing Capacity	1-15

Chapter 2

2.4-A	Explanation of Box-and-Whiskers Plot	2-4
-------	--------------------------------------	-----

Chapter 3

3.2-A	Worldwide Biopharmaceutical Contract Manufacturing Capacity	3-10
3.3-A	Number of Products Outsourced versus Produced In-House	3-13
3.3-B	Outsourced Products by Development Stage in 2011	3-13
3.3-C	Percentage of Respondents' Portfolio Outsourced by Production Technology	3-14
3.3-D	Tank Sizes Required for Outsourced Microbial Fermentation Products	3-15
3.3-E	Tank Sizes Required for Outsourced Mammalian Cell Culture Products	3-15
3.3-F	Simple Averaged Expected Percentages of Overall Outsourced Production	3-21
3.3-G	Trends by Number of Products Outsourced by Phase	3-23
3.3-H	Trends by Number of Products Outsourced by Technology	3-24
3.4-A	Mammalian Outsourcing Demand versus Contract Capacity: 2011 to 2016	3-27
3.4-B	Microbial Outsourcing Demand versus Contract Capacity: 2011 to 2016	3-29
3.6-A	Size of the Worldwide Biopharmaceutical Contract Manufacturing	3-34

Chapter 4

4.2-A	Percentage of Respondents by Number of Biomanufacturing Sites	4-4
4.2-B	Number of Biopharmaceutical Products on Market	4-6
4.2-C	Respondents' Biopharmaceutical Products by Technology and Phase	4-8
4.2-D	Respondents' 111 Biopharmaceutical Products by Phase	4-8
4.2-E	Respondents' 111 Biopharmaceutical Products by Company Type	4-9
4.2-F	Number of Products Outsourced versus Produced In-House	4-10
4.2-G	Outsourced Products by Phase in 2011	4-11
4.2-H	Outsourced Products by Phase by Year	4-12
4.2-I	Tanks Sizes Required for Outsourced Microbial Fermentation Products	4-14
4.2-J	Tanks Sizes Required for Outsourced Mammalian Cell Culture Products	4-14

Biopharmaceutical Contract Manufacturing 2011: New Participants, Expanded Services and Emerging Markets

LIST OF FIGURES (continued)

Chapter 4

4.3-A	Summation of Outsourced Volumes Required by Respondents	4-20
4.3-B	Respondents' Preclinical Products	4-23
4.3-C	Preclinical Production Outsourcing	4-24
4.3-D	Amount of Preclinical Production Outsourcing by Company Type	4-25
4.3-E	Technology Usage Patterns Top 6 Mentions	4-28
4.4-A	Respondents' Outsourcing Strategies	4-30
4.4-B	Outsource Decision if Have In-House Capacity and Capability	4-36
4.4-C	Outsource Production Planning Process	4-40
4.4-D	Consideration of Second Source	4-46
4.4-E	Number of New Projects Outsourced Over Last 3 Years	4-50
4.5-A	Average Percentages of Outsourced Production	4-52
4.5-B	Average Percentages of Outsourced Budget: 2011	4-54
4.5-C	Numbers of Respondents Increasing, Decreasing, or Keeping the Same Outsourcing Percentage	4-55
4.5-D	Most Important Outsource Services by Segment: Manufacturing Sites	4-59
4.5-E	Most Important Outsource Services by Segment: Commercial Production	4-60
4.6-A	Expression Levels by Phase and Technology	4-66
4.6-B	Final Release of API	4-68
4.6-C	Presence of Disruptive Technologies	4-72
4.6-D	Potential Disruptive Technologies	4-73
4.7-A	Search Modes for CMOs	4-79
4.7-B	When Users Begin Their CMO Search	4-81
4.7-C	Top Criteria for Selecting a CMO	4-90
4.7-D	Top Five Weighted Characteristics by Number of Manufacturing Sites	4-92
4.7-E	CMO Selection Characteristics for Different Technology	4-93
4.7-F	Use of Internet for CMO Search	4-102
4.7-G	Outsourcing to a CMO in Low-Cost Region	4-111
4.7-H	Knowledge of Possible Asian CMO Competitors	4-118
4.7-I	Location of Possible Asian CMO Competitors	4-118
4.7-J	Biologic API Production Moving to Asian CMO	4-122
4.8-A	Average Duration of a CMO Contract – Commercial	4-134
4.8-B	Average Duration of a CMO Contract – Clinical	4-135
4.8-C	Preferred Outsourcing Service Model	4-139
4.8-D	Awareness of Other Services Models	4-142
4.9-A	Respondents Expected Change in Outsourcing Budgets: 2011 to 2013	4-150
4.9-B	Average Percentage of Budgets Spent on Each Technology: 2011 and 2013	4-152
4.9-C	Payment of Upfront Reservation Fees	4-160
4.9-D	Reasonableness of Charging a Materials Markup	4-163
4.10-A	Companies Building Large-Scale Facilities	4-174

Biopharmaceutical Contract Manufacturing 2011: New Participants, Expanded Services and Emerging Markets

LIST OF FIGURES (continued)

Chapter 5

5.1-A	Year Respondent Company Entered into CMO Business	5-4
5.1-B	Contract Biomanufacturers' Annual Revenue Ranges in US\$ in 2010	5-13
5.2-A	Technology Comparisons: Average Percentage of Business: 2011 by Group	5-15
5.2-B	Technology Comparisons: Average Weighted Percentage of Business: 2011	5-16
5.2-C	Service Category Comparisons: Average Percentage of Business: 2011	5-19
5.2-D	Production Category Comparisons: Average Percentage of Business: 2011	5-19
5.2-E	Average Percentage of Revenue from Each Service Category: Weighted	5-20
5.2-F	Individual Microbial Fermentation Capacity Utilization Rates: 2011/2013	5-23
5.2-G	Individual Mammalian Cell Culture Capacity Utilization Rates: 2011/2013	5-25
5.2-H	Summary of Current and Future Capacity at Surveyed Contractor Facilities	5-28
5.3-A	Manufacture of Commercial Products	5-29
5.3-B	Number of Commercial Products Produced	5-30
5.3-C	Location of Contractors Producing Commercial Products	5-30
5.3-D	Distribution of Respondents Using Instruments and Technology for PAT	5-35
5.3-E	Future Use of Proprietary or Generic Expression Platforms	5-39
5.3-F	Average Time to Change from Product A to Product B	5-43
5.3-G	How Product Change Time is Charged	5-44
5.3-H	Timeline Distribution	5-47
5.3-I	Expression Yields by Technology and Contractor Size	5-48
5.3-J	Batch Success Rates	5-49
5.4-A	Average Number of RFPs Received Each Month	5-50
5.4-B	Average Percentage of RFP Proposal Success Rates	5-51
5.4-C	Number of Clients Served in 2010	5-59
5.4-D	Number of Projects Worked on in 2010	5-60
5.4-E	Percentage of Business from Different Customer Groups by Company Type	5-63
5.4-F	Percentage of Business from the World Regions by Company Type	5-65
5.4-G	Contract Duration	5-66
5.5-A	CMO's Biosimilars Strategy	5-73
5.5-B	Proportion of Biosimilar Business by Contractor Respondent	5-76
5.6-A	Change in Demand for Outsourced Services Over Last 12 Months	5-80
5.6-B	Expectations of Industry Growth: Twelve Months and Three Years	5-90
5.6-C	Expectation Growth will Change in the Next Three Years	5-91
5.6-D	Comparative Expectation of Growth of Mammalian and Microbial Technologies	5-92